Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities

被引:14
|
作者
Lim, Ji-Hun [1 ]
Seo, Eul-Ju [1 ]
Park, Chan-Jeoung [1 ]
Jang, Seongsoo [1 ]
Chi, Hyun-Sook [1 ]
Suh, Cheolwon [2 ]
Kim, Hawk [3 ]
Kim, Sung-Ryul [4 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Div Hematol Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Lab Med, Seoul, South Korea
关键词
multiple myeloma; cytogenetics; 1q amplification; complex chromosomal abnormality; hyperdiploidy; GENETIC ABNORMALITIES; TRANSLOCATIONS; HYPODIPLOIDY; KARYOTYPE; DIAGNOSIS; DELETIONS; SURVIVAL; 1Q;
D O I
10.1111/ejh.12257
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chromosomal abnormalities are important prognostic factors for patients diagnosed with multiple myeloma (MM). We retrospectively reviewed the clinical and laboratory data of 525 MM patients to assess the abnormalities frequently found by conventional cytogenetic analysis and to determine their relationship to prognosis and clinical parameters. Samples from 222 (42.3%) patients had abnormal karyotypes. Hyperdiploidy-1 (>50 chromosomes), hyperdiploidy-2 (47-50 chromosomes), pseudodiploidy (46 with abnormalities), and hypodiploidy (<46 chromosomes) were found in 55, 44, 42, and 81 patients, respectively. The median overall survival (OS) was significantly shorter in patients with hyperdiploidy-2 (20.9months), pseudodiploidy (19.9months), and hypodiploidy (18.3months) compared with patients with normal karyotype (66months) and hyperdiploidy-1 (55.4months) (P<0.001). Among patients with chromosomal abnormalities, those with 1q amplification had a shorter median OS (17 vs. 25.1months, P=0.018). Patients with a chromosome 13 deletion in the pseudodiploidy group also had a shorter OS. A karyotype with more than six structural abnormalities was found to have the most significant independent prognostic value by multivariate analysis. These data show that hyperdiploidy with 47-50 chromosomes should be recategorized as an unfavorable risk group, and the number of structural abnormalities needs to be considered as an important factor for prognosis. In conclusion, our findings imply that subclassification of chromosomal abnormalities by conventional cytogenetics could be applied to the prognostic assessment of MM.
引用
收藏
页码:313 / 320
页数:8
相关论文
共 37 条
  • [1] STRUCTURE AND SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA
    Abramova, T., V
    Obukhova, T. N.
    Gribanova, E. O.
    Solovev, M. V.
    Firsova, M. V.
    Votyakova, O. M.
    Kulikov, S. M.
    Chabaeva, Yu A.
    Gal'tseva, I., V
    Mendeleeva, L. P.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2021, 66 (01): : 54 - 67
  • [2] Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji K.
    BLOOD, 2015, 126 (23)
  • [3] Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
    M Binder
    S V Rajkumar
    R P Ketterling
    A Dispenzieri
    M Q Lacy
    M A Gertz
    F K Buadi
    S R Hayman
    Y L Hwa
    S R Zeldenrust
    J A Lust
    S J Russell
    N Leung
    P Kapoor
    R S Go
    W I Gonsalves
    R A Kyle
    S K Kumar
    Blood Cancer Journal, 2016, 6 : e401 - e401
  • [4] Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2016, 6 : e401 - e401
  • [5] Prevalence and Prognostic Impact of Cytogenetic Abnormalities in 220 Patients With Multiple Myeloma
    Abe, Yoshiaki
    Fujisawa, Manabu
    Usui, Yoshiaki
    Narita, Kentaro
    Takeuchi, Masami
    Matsue, Kosei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E29 - E29
  • [6] Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
    Merz, Maximilian
    Jauch, Anna
    Hielscher, Thomas
    Bochtler, Tilmann
    Schoenland, Stefan Olaf
    Seckinger, Anja
    Hose, Dirk
    Bertsch, Uta
    Neben, Kai
    Raab, Marc Steffen
    Hillengass, Jens
    Salwender, Hans
    Blau, Igor Wolfgang
    Lindemann, Hans-Walter
    Schmidt-Wolf, Ingo G. H.
    Scheid, Christof
    Haenel, Mathias
    Weisel, Katja C.
    Goldschmidt, Hartmut
    BLOOD ADVANCES, 2018, 2 (01) : 1 - 9
  • [7] CLINICAL CHARACTERISTICS AND PROGNOSTIC SIGNIFICANCE OF HEPATITIS VIRUS INFECTION IN PATIENTS WITH MULTIPLE MYELOMA AND ITS ASSOCIATION WITH CYTOGENETIC ABNORMALITIES
    Teng, C. J.
    Yu, Y. B.
    Liu, H. T.
    Liu, C. Y.
    Hong, Y. C.
    Hsiao, L. T.
    Gau, J. P.
    Liu, J. H.
    Chiou, T. J.
    Chen, P. M.
    Tzeng, C. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 580 - 580
  • [8] Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
    Jian, Yuan
    Chen, Xiaolei
    Zhou, Huixing
    Zhu, Wanqiu
    Liu, Nian
    Geng, Chuanying
    Chen, Wenming
    MEDICINE, 2016, 95 (19)
  • [9] The Prognostic Significance of Vitamin D Deficiency in Korean Patients With Multiple Myeloma
    Kim, Sejin
    Cho, Hyungwoo
    Kim, Miyoung
    Lee, Kyoungmin
    Kim, Shin
    Yoon, Dok Hyun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : e112 - e118
  • [10] Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation
    Greslikova, H.
    Zaoralova, R.
    Filkova, H.
    Nemec, P.
    Oltova, A.
    Kupska, R.
    Rudolecka, P.
    Smetana, J.
    Pour, L.
    Zahradova, L.
    Krejci, M.
    Buchler, T.
    Adam, Z.
    Hajek, R.
    Kuglik, P.
    NEOPLASMA, 2010, 57 (02) : 111 - 117